Cart
sales@molnova.com
MRT-2359
CAS No. 2803881-11-8
MRT-2359( —— )
Catalog No. M36092 CAS No. 2803881-11-8
MRT-2359 is a potent and orally available GSPT1 reducer with antitumour activity.MRT-2359 inhibits the growth of drug-resistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.MRT-2359 exhibits preferential activity in MYC-driven cell lines.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 177 | In Stock |
|
| 5MG | 106 | In Stock |
|
| 10MG | 179 | In Stock |
|
| 25MG | 359 | In Stock |
|
| 50MG | 576 | In Stock |
|
| 100MG | 872 | In Stock |
|
| 200MG | 1172 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMRT-2359
-
NoteResearch use only, not for human use.
-
Brief DescriptionMRT-2359 is a potent and orally available GSPT1 reducer with antitumour activity.MRT-2359 inhibits the growth of drug-resistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.MRT-2359 exhibits preferential activity in MYC-driven cell lines.
-
DescriptionMRT-2359 is an orally active and potent degrader of GSPT1 (IC50: >30 nM and <300 nM) with anti-tumor activity. MRT-2359 also inhibits the growth of resistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells. MRT-2359 exhibits preferential activity in MYC-driven cell lines, such as N- and L-MYC high NSCLC and SCLC patient-derived xenografts (PDXs).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2803881-11-8
-
Formula Weight495.38
-
Molecular FormulaC22H17F4N3O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (201.87 mM; Ultrasonic )
-
SMILESO=C1N(CC=2C1=CC(COC(NC3=CC(OC(F)(F)F)=CC=C3F)=O)=CC2)C4C(=O)NC(=O)CC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gavory G, et al. Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction[J]. Cancer Research, 2023, 83(7_Supplement): 3449-3449.
molnova catalog
related products
-
Plantamajoside
Plantamajoside has anti-hepatotoxic, anti-inflammatory, antinociceptive activities, improving sexual function and antioxidant activity.
-
BLU0588
BLU0588 is a selective PRKACA inhibitor. BLU0588 inhibits PRKACA catalytic activity with a half-maximal inhibitory concentration (IC50) of 1 nM.
-
Verdiperstat
Verdiperstat (AZD-3241) is a potent, selective, reversible, orally active myeloperoxidase (MPO) inhibitor with IC50 of 630 nM, >14-fold selectivity over thyroid peroxidase (TPO).
